Please assess the completion status of the following clinical trial:

Trial Title: RADAR Trial - Randomised Androgen Deprivation and Radiotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Histological confirmation of adenocarcinoma of the prostate in the three months prior to randomisation~* Gleason primary and secondary pattern reported. If the volume of tumour in biopsies is too small for the pathologist to allocate a secondary pattern, the primary pattern alone is sufficient.~* Primary tumour stage T2b - 4 (UICC 2002), or T2a providing biopsies demonstrate Gleason score 7 or more, and presenting PSA 10 or more~* PSA value obtained within one month of randomisation~* No evidence of lymphatic or haematogenous metastases, as determined by negative chest x-ray, CT scan of abdomen and pelvis, and bone scan in the 3 months prior to randomisation~* ECOG performance status 0 - 1~* No concurrent medical conditions likely to significantly reduce prospects of 5 year survival~* Patient accessible to follow up at intervals specified in protocol~* Written informed consent given (signed by both patient and investigator prior to randomisation)~Exclusion Criteria:~* Previous or concurrent malignancy within previous 5 years except for non-melanomatous skin cancer~* Prostatectomy~* Prior pelvic radiotherapy~* Prior hormone treatment for prostate cancer~* Inability to complete self administered QOL questionnaire~* Prior bisphosphonate therapy~* Serum creatinine \> 2 x ULN~* Osteoporosis resulting in \>30% loss in vertebral height in one or more thoraco-lumbar vertebrae~* Liver disease resulting in ALT or AST levels \>3 x ULN~* Prolonged continuous glucocorticoid therapy \> 10 mg/day of prednisone equivalent (\>6 months)~* Current treatment with bisphosphonate~* Inability to attend for follow-up at the Investigator's clinic

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): LH-RH analogue for 5 months prior to and during first month of radiation treatment (total 6 mths)
- B (Type: ACTIVE_COMPARATOR): LH-RH analogue for 5 months prior to and during first month of radiation treatment (total 6 months) + bisphosphonate therapy.
- C (Type: EXPERIMENTAL): LH-RH analogue as for arm A, but continued for further 12 months (total 18 months)
- D (Type: EXPERIMENTAL): LH-RH analogue as for arm A, but continued for further 12 months (total 18 months) + bisphosphonate therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).